MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in
treating patients with solid tumors that have spread to other places in the body and usually
cannot be cured or controlled with treatment (advanced). Adavosertib, everolimus, and
trametinib are drugs that each target a specific variation in tumors by blocking different
proteins needed for cell growth. Veliparib blocks an enzyme that helps repair
deoxyribonucleic acid (DNA) damaged by chemotherapy, which may help chemotherapy drugs work
better. It is not yet known whether testing patients for variations in their tumor and
assigning treatment targeting the variation is more effective than standard non-targeted
therapy in treating advanced solid tumors.